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Tbjective: Although endovascular repair of the descending thoracic aorta has
merged as a viable treatment option, little is known about its potential to treat
atients diagnosed with aortobronchial fistulas. We reviewed our comprehensive
horacic endografting experience with regard to the endovascular management and
ubsequent outcome of patients with aortobronchial fistulas to assess whether
ndoluminal graft repair is a realistic option.
ethods: Between February 2000 and November 2005, 255 patients were success-
ully treated with an endoluminal graft to the descending thoracic aorta. Indications
or intervention included: atherosclerotic aneurysms (109/255, 42.7%), acute and
hronic dissections (75/255, 29.4%), miscellaneous (34/255, 13.3%), penetrating
ortic ulcers (30/255, 11.8%), and aortobronchial fistulas (7/255, 2.7%).
esults: Average patient age was 73.4  10.1 years, with 4 male patients (4/7,
7.1%) and 3 female patients (3/7, 42.9%). All patients presented with hemoptysis,
ith 1 patient (1/7, 14.3%) requiring preoperative blood transfusion. Three patients
3/7, 42.9%) were diagnosed with atherosclerotic aneurysms, 3 patients (3/7, 42.9%)
ad pseudoaneurysms associated with prior open surgical repair, and 1 patient (1/7,
4.3%) had a prior endoluminal graft placed for a traumatic aortic transection. No
tandard postoperative antibiotic regimen was followed. There were no endoleaks,
o incidences of paraplegia, and no endoluminal graft infections. Survival was
00% (7/7) at both 30 days and 1 year, and all patients are currently alive. Follow-up
omputed tomography was available for all 7 patients, with an average follow-up of
2.6  28.5 months.
onclusions: Endovascular management of aortobronchial fistulas appears to be
afe and well tolerated, even in surgically high-risk patients, with minimal risk of
rosthesis infection. Long-term surveillance and continued investigation are war-
anted.
ortobronchial fistulas (ABFs) can be associated with a number of patho-
logic conditions of the descending thoracic aorta (DTA), including athero-
sclerotic aneurysms, para-anastomotic pseudoaneurysms secondary to pre-
ious open surgical repair, and mycotic aneurysms.1-3 In addition, ABFs have been
ssociated with invasive aspergillus infection of the lung, unilateral lung transplan-
ation, and pulmonary tuberculosis.4-6 Usually presenting as massive and/or inter-
ittent hemoptysis, a high index of suspicion and early diagnosis are critical.
lthough rare, this life-threatening disorder requires urgent intervention and treat-
ent. The operative mortality for traditional open surgical repair of ABF using the
lamp-and-sew technique reaches 20% in the modern era.7
As endovascular repair of the DTA is emerging as a viable treatment option for
ncomplicated atherosclerotic aneurysms, little is known about its potential to treat
atients diagnosed with ABF. Currently, only 1 thoracic endoprosthesis has gained
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1277
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ETpproval by the United States Food and Drug Administra-
ion for endovascular treatment of the DTA. Use of this
evice is limited to atherosclerotic aneurysms; however,
everal case reports have been published describing endo-
ascular stent-graft repair of ABF using several different
ypes of thoracic endoprostheses.8-10 The results have been,
n general, favorable. We reviewed our comprehensive tho-
acic endografting experience with regards to the endovas-
ular management and subsequent outcome of patients with
BF to assess whether endovascular stent-graft repair is a
ealistic option.
aterials and Methods
etween February 2000 and November 2005, 255 consecutive
atients with diverse pathologies of the DTA were prospectively
nrolled in an Arizona Heart Hospital Institutional Review Board–
pproved single-site investigational device exemption clinical
tudy. All patients were treated with TAG endoprostheses (W. L.
ore & Associates, Flagstaff, Ariz) under the investigational pro-
ocol and were fully informed and consented prior to implantation
f the endoluminal graft (ELG). Enrollment in the study was
imited to patients who were deemed to be at “high surgical risk,”
eaning that they had comorbidities and/or thoracic aortic pathol-
gies that placed them at prohibitive risk for open repair, and,
Abbreviations and Acronyms
ABF  aortobronchial fistula
CFA  common femoral artery
CT  computed tomography
DTA descending thoracic aorta
ELG  endoluminal graft
IDE  investigator device exemption
TEE  transesophageal echocardiogram
ABLE 1. Characteristics of patients with aortobronchial fi
ge (y)/sex Aortic pathology
52/M Pseudoaneurysm; prior DTA aneurysm
repair  2
75/M Pseudoaneurysm, prior DTA aneurysm
repair, new DTA aneurysm,
abdominal aortic dissection
75/F Pseudoaneurysm, prior DTA aneurysm
repair
77/F DTA aneurysm
75/M DTA aneurysm, penetrating aortic ulcer
71/F DTA aneurysm
69/M Prior thoracic ELG for aortic transection
(6 y prior)
M, Diabetes mellitus; HTN, hypertension; CHF, congestive heart failure; CO
nsufficiency; CVA, cerebral vascular accident; MVA, motor vehicle accident; D
278 The Journal of Thoracic and Cardiovascular Surgery ● Maithout intervention, an adverse event could be anticipated within
ays or weeks. During this study period, no patients were treated
onoperatively or with open surgery.
Seven patients with ABF were treated (Table 1). Mean age was
3.4  10.1 years, with 4 male patients (4/7, 57.1%) and 3 female
atients (4/7, 42.9%). All patients with ABF presented with he-
optysis (n  7). Patients with ABF were diagnosed preopera-
ively based upon clinical findings of hemoptysis and diagnostic
ests, which included chest radiography (n 7), contrast-enhanced
omputed tomography (CT) angiography (n 7), bronchoscopy (n
5), angiography (n  3), and transesophageal echocardiography
n  3). All patients were hemodynamically stable at the time of
heir intervention.
Following discharge, patients were seen within 2 weeks to
ssess the incision sites and to evaluate the patient’s overall health
tatus. CT scans, plain radiographs, and physical examinations
ere obtained at 1, 6, and 12 months and yearly thereafter. All
ignificant medical events that resulted in either an unplanned
ncrease in the level of care, permanent sequela, or death were
ecorded.
esults
he TAG endoprosthesis was successfully delivered and
eployed in all 7 patients (7/7, 100%), with no open thoracic
onversions. Adequate ELG placement and exclusion of the
BF was confirmed by completion angiography. Ten ELGs
ere deployed in 7 patients. Table 2 lists the sizes of the
LGs deployed along with the method of vascular access
or sheath delivery. In 2 patients, the external iliac artery
as too small to accommodate the delivery sheath; a retro-
eritoneal incision was performed, and a 10-mm Dacron
onduit was anastomosed to the proximal common iliac
rtery. The conduit was then used to deliver both the sheath
nd the device. In 2 patients, the conduit was ligated, and in
patient the conduit was tunneled to the ipsilateral common
as treated with an endoluminal graft
ptoms Comorbidities
optysis Active tobacco use
optysis Type II DM, HTN, aortic valve replacement, CHF,
atrial fibrillation
optysis HTN, COPD, MI, CVA, CHF, severe AI, ulcerative
colitis, home oxygen
optysis Renal insufficiency, COPD, active tobacco use
optysis HTN, prior abdominal aortic aneurysm repair with
ELG, peripheral vascular disease
optysis HTN, COPD, prior ascending aortic aneurysm
repair, active tobacco use
optysis MVA, HTN, aortic transection, multiple abdominal
surgeries, hepatitis B
hronic obstructive pulmonary disease; MI, myocardial infarction; AI, aorticstul
Sym
Hem
Hem
Hem
Hem
Hem
Hem
Hem
PD, c
TA, descending thoracic aorta; ELG, endoluminal graft.
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ETemoral artery (CFA), and an iliac-CFA bypass was per-
ormed. In the other 4 patients, vascular access and sheath
elivery were safely performed through the CFA. There
ere no iliac artery ruptures secondary to sheath delivery or
emoval and no complications associated with vascular
ccess.
To better define the most proximal extent of the landing
oint for the ELG, the thoracic aorta has been divided into
everal zones. Zone 1 is the ascending aorta up to and
ncluding the origin of the innominate artery; zone 2 in-
ludes the origin of the left common carotid artery; zone 3
ncludes the origin of the left subclavian artery and proximal
TA; and zone 4 is the mid to distal DTA. The ELG was
anded in zone 2 in 1 patient with intentional coverage of the
eft subclavian artery, zone 3 in 5 patients, and zone 4 in 1
atient. In the patient who required coverage of the left
ubclavian artery to achieve adequate proximal fixation,
he subclavian artery was not coil embolized, and no
arotid-subclavian bypass was performed. This patient
ad no signs of arm or hand ischemia and was completely
symptomatic. Neurologically, there were no cerebral vas-
ular accidents or transient ischemic attacks associated with
he procedures. There were no incidences of paraparesis or
araplegia. We elected not to utilize spinal drains in any of
he patients and maintained increased spinal perfusion by
aintaining a systolic blood pressure greater than 140 mm
g for 48 hours postoperatively. We did not monitor spinal
ord somatosensory evoked potentials.
Postoperatively, there were no significant episodes of
rrhythmias or ST segment changes noted on telemetry
onitoring. There were no episodes of chest pain or myo-
ardial infarctions. One patient developed midback and rib
ain on postoperative day 1, which resolved spontaneously
y postoperative day 4. Two patients required blood trans-
usions with each patient receiving 1 U of packed red blood
ells. The average amount of nonionic contrast used for the
rocedures was 336.4  206.7 mL (range 120–640 mL).
here were no episodes of acute renal insufficiency second-
ABLE 2. Number and sizes of thoracic endoprostheses u
atient # Number of endoprostheses
1 1
2 2
3 1
4 1
5 1
6 2
7 2ry to contrast nephropathy, and all patients were aggres- g
The Journal of Thoracicively hydrated intravenously with normal saline solu-
ion. One patient had a baseline creatinine level of 2.0
g/dL and was discharged with a creatinine level of 1.9
g/dL. This patient received a fenoldopam intravenous
rip pre- and postoperatively to assist in minimizing
ontrast nephropathy.
All patients received a CT angiogram of the chest, ab-
omen, and pelvis prior to discharge. There were no en-
oleaks or ELG migrations detected. All ABFs appeared to
ave sealed by the time of the CT angiogram, and there was
tability of the aortic diameter over time (Figure 1). The
emoptysis resolved in all patients prior to discharge. All
atients received intravenous doses of cefazolin periopera-
ively. No standard antibiotic regimen was implemented.
ive patients were discharged home on oral antibiotics, and
 patients were not discharged on any antibiotics (Table 3).
here were no clinically documented pneumonias and no
igns of infection in any of the patients. The average length
f stay in the hospital was 4  1.1 days (range 3–6 days).
ith vascular access
Endoprostheses sizes Vascular access
28 mm  7 cm Common femoral artery
34 mm  20 cm Common femoral artery
40 mm  10 cm
34 mm  20 cm Retroperitoneal conduit
37 mm  15 cm Retroperitoneal conduit
40 mm  20 cm Common femoral artery
37 mm  20 cm Common femoral artery
37 mm  10 cm
34 mm  20 cm Common femoral artery
34 mm  15 cm
igure 1. Aortic diameter (cm) in patients with ABFs treated with
n ELG preoperatively and at regularly scheduled postoperative
ollow-up intervals. ABF, Aortobronchial fistula; ELG, endoluminalsed wraft.
and Cardiovascular Surgery ● Volume 133, Number 5 1279
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1
EThere were no deaths and no reinterventions at 30 days
ostoperatively. Average follow-up was 42.6  28.5
onths (range 10–75 months). All patients are currently
live (7/7, 100%), and no patient has complained of hemop-
ysis. There have been no episodes, observed either clini-
ally or by CT scan, of ELG infection. There have been no
evice fractures or migrations and no endoleaks. There have
een no reinterventions.
Only 1 patient required an additional vascular interven-
ion. This patient underwent successful placement of an
nfrarenal abdominal aortic ELG for an expanding 5-cm
bdominal aortic aneurysm 4 years after treatment of the
BF. Three patients have been diagnosed with new medical
roblems. One patient has developed bladder cancer 5 years
fter treatment of his ABF, and the bladder cancer is cur-
ently controlled with chemotherapy bladder irrigations.
nother patient required insertion of a dual-chamber pace-
aker for new sick sinus syndrome 2 years following ELG
nsertion and has also experienced a recent cerebral vascular
ccident. A third patient has developed a new 2-cm pulmo-
ary nodule, which was detected during routine chest CT
maging for ELG surveillance, and has also developed mild
enal insufficiency 3 years following ELG insertion. Three
atients have had no new medical problems and are other-
ise healthy.
iscussion
BFs represent a challenging therapeutic and diagnostic
ilemma. Presenting as either intermittent or massive he-
optysis, mortality is 100% if intervention is not pursued
ggressively.11 The fistulous connection results from com-
ression necrosis of the posterior aspect of the left tracheo-
ronchial tree from an associated aneurysm or pseudoaneu-
ysm of the DTA. The size of the fistulous connection
etermines the magnitude of the hemoptysis. If left un-
reated, the fistula can continue to enlarge until massive
emoptysis and possibly exsanguination occur. In addition
o hemoptysis, additional signs and symptoms of ABF are
ABLE 3. Antibiotic administration in patients with aortob
atient Perioperative
#1 Cefazolin 1 g IV q8h  3 doses Ceftazidim
Ciprofloxi
#2 Cefazolin 1 g IV q8h  3 doses None
#3 Cefazolin 1 g IV q8h  3 doses None
#4 Cefazolin 1 g IV q8h  3 doses Vancomy
#5 Cefazolin 1 g IV q8h  3 doses Levofloxa
#6 Cefazolin 1 g IV q8h  3 doses Levofloxa
#7 Cefazolin 1 g IV q8h  3 doses Ampicillin
(9 dose
V, Intravenous; PO, per oral; BID, twice daily; QD, once daily; QID, four tyspnea and cough, chest or back pain, pulmonary rales, or s
280 The Journal of Thoracic and Cardiovascular Surgery ● Maypoxia.12 This disorder can often be confused with pulmo-
ary embolism, pneumonia, or lung abscess, and therefore a
igh index of suspicion is important.
Several imaging modalities are useful in diagnosing ABF
nd in differentiating it from other sources of hemoptysis.
hest radiograph, chest CT with intravenous contrast, mag-
etic resonance imaging, and contrast aortography have all
een shown to be successful in demonstrating ABF (Figures
, 3).2,11 In addition, bronchoscopy, intravascular ultra-
ound, and transesophageal echocardiogram (TEE) are use-
ul modalities for making the diagnosis. Bronchoscopy is
articularly useful in ruling out other pulmonary sources of
he hemoptysis but should be pursued with caution because
f the risk of dislodging any clot and potentially reactivating
leeding. In all of our patients, bronchoscopy and chest CT,
adiograph, and aortogram were used to confirm the diag-
osis. In addition to assisting with making the diagnosis,
oth intravascular ultrasound and TEE can assist with in-
raoperative visualization and localization of the ABF and
elp with identifying the appropriate location for stent-graft
eployment. We believe that these two imaging modalities
hial fistulas treated with an endoluminal graft
stoperative Outpatient
g IV q12h  4 doses
00 g PO  1 dose
Ciprofloxicin 500 mg PO BID (5 d)
None
None
g IV  1 dose Cephalexin 500 mg PO QID (7 d)
00 mg IV  2 dose Levofloxacin 500 mg PO QD (10 d)
00 mg IV  2 dose Levofloxacin 500 mg PO QD (7 d)
actam 1.5 g IV q8h Levofloxacin 500 mg PO QD (14 d)
daily.
igure 2. Chest CT demonstrating an ABF (white arrow) from the
TA to the left main stem bronchus. CT, Computed tomographicronc
Po
e 1
cin 5
cin 1
cin 5
cin 5
/sulb
s)can; ABF, aortobronchial fistula.
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ETre critical for identifying suitable proximal and distal land-
ng zones for the ELG and ensuring that the ABF is
xcluded.
Most patients with ABF have complex aortic pathologic
onditions, such as para-anastomotic pseudoaneurysms or
izeable atherosclerotic aneurysms of the DTA, which make
pen surgical repair a less than straightforward procedure.
n addition to the technical challenges of performing a redo
eft thoracotomy or dealing with a complex DTA aneurysm,
he potential exists for prosthetic graft infection. A recent
9-year review of cases of ABF treated with open surgical
epair revealed an operative mortality of 20% with no
ssociated embolic strokes or paraplegias.7 In addition,
ollow-up with a median of 2.5 years showed no deaths.7
espite improved results with open surgical repair, an op-
ortunity exists to potentially incorporate less invasive tech-
ologies, such as endovascular stent-graft repair, into the
reatment paradigm for ABF (Figure 4).
A review of the literature shows a total of 36 cases of
BF treated with an ELG (Table 41,2,4,9,13-28). A meta-
nalysis demonstrates a cumulative 30-day mortality of
.3%, with most of the cases reporting successful 1-year
urvival. In our cohort of 7 patients, we were able to
uccessfully treat the ABF with an ELG in all patients.
lthough all patients presented with hemoptysis, only 2
atients required a blood transfusion for a hemoglobin value
10 g/dL. The relatively low transfusion rate in our patients
s attributed to early recognition and intervention, which
llowed us to repair the ABF prior to catastrophic hemor-
hage and prevent additional blood loss. Survival was 100%
t both 30 days and 1 year. All patients are currently alive
p to 75 months postprocedure and have required no rein-
igure 3. Diagnostic angiogram demonstrating an ABF (white
rrow) from the DTA to the left main stem bronchus at the site of
pseudoaneurysm. ABF, Aortobronchial fistula; DTA, descending
horacic aorta.erventions. Only 1 patient has required a subsequent vas- ‡
The Journal of Thoracicular intervention. This patient required ELG repair for an
xpanding abdominal aortic aneurysm.
We did not utilize spinal cord protection with a spinal
rain in any of the patients in this study. In addition, we do
ot utilize somatosensory evoked potential monitoring for
ur thoracic endografting procedures. There were no peri-
perative or postoperative neurologic complications, such
s paraplegia or paraparesis. We use a spinal drain selec-
igure 4. Chest CT demonstrating successful exclusion of an
BF. CT, Computed tomographic scan; ABF, aortobronchial fistula.
ABLE 4. Meta-analysis of all previously published cases
f endoluminal graft repair of aortobronchial fistulas
Author (year) Number of patients 30-day survival
ampagna (1996) 1 1/1 (100%)
huter (1996) 1 1/1 (100%)
army-Jones (1999) 1 1/1 (100%)
iyata (1999) 2 2/2 (100%)
orweller (2001) 3 3/3 (100%)
mayra (2001) 1 1/1 (100%)
iati (2001) 1 1/1 (100%)
oo (2001) 1 1/1 (100%)
ramer (2001) 1 1/1 (100%)
eobon (2002) 3 2/3 (66%)
hompson (2002) 4* 4/4 (100%)
itton (2002) 4 4/4 (100%)
ochi (2002) 1 1/1 (100%)
rend (2003) 1 1/1 (100%)
ockler (2004) 8 6/8 (75%)
uman (2004) 1 1/1 (100%)
halhammer (2004) 1 1/1 (100%)
hare (2005) 1 1/1 (100%)
slam (2005) 1 1/1 (100%)
aw (2005) 1 1/1 (100%)
unneke (2006) 1 1/1 (100%)
heatley (2006) 4† 4/4 (100%)
otal 36‡ 33/36 (91.7%)
Two patients included in this study. †Four patients included in this study.
Exclusive of patients already included in this study.
and Cardiovascular Surgery ● Volume 133, Number 5 1281
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1
ETively for neurologically high-risk patients, and we place the
rain preoperatively in patients with a prior abdominal
ortic aneurysm repair (open or endovascular) and/or ma-
ipulation of the DTA below the level of T9. In addition, if
ny patient develops postoperative paraplegia or parapare-
is, we will immediately place a spinal drain. Following
LG repair, we help prevent spinal cord ischemia by ac-
ively increasing the systolic blood pressure to between 140
nd 160 mm Hg for 48 hours postoperatively. The subcla-
ian artery is also an important contributor to spinal cord
erfusion and collaterals; however, it can frequently be
overed without neurologic or vascular compromise.28 We
ntentionally covered the left subclavian artery in 1 patient
n this study to achieve adequate 2-cm proximal fixation of
he ELG. We did not perform a preoperative carotid-
ubclavian bypass in this patient, and there were no neuro-
ogic sequelae. In addition, there was no retrograde type II
ndoleak from the left subclavian artery, and the patient had
o signs of vascular insufficiency of the left arm. We have
ound that it is safe to manage these patients expectantly,
nd if left arm claudication develops, then we perform an
lective carotid-subclavian bypass.
Vascular access is an important consideration for tho-
acic endografting procedures. Introduction and removal of
arge-bore delivery sheaths in small, calcified or tortuous
ccess vessels can be associated with rupture of the iliac
rtery and subsequent patient mortality. It is critical to
ssess the quality and size of both external and external iliac
rteries in patients who are candidates for endovascular
epair to see if the arteries will accommodate the large-bore
elivery sheath before the patient can be offered endovas-
ular repair. If the access vessels will not accept the large-
ore delivery sheath, then a 10-mm retroperitoneal conduit
ust be sewn to the distal aorta or proximal common iliac
rtery to make the vascular access portion of the procedure
afe. In this study, 3 patients (3/7, 42.9%) required a retro-
eritoneal conduit to safely deliver the sheath. This rate is
ignificantly higher than most series for thoracic endograft-
ng. Commonly, 15% of patients who are treated with a
horacic ELG require a retroperitoneal conduit.29 It is unclear
hy our series has a higher rate of retroperitoneal conduits, but
of the 7 patients had aggressive atherosclerotic-related dis-
ase as their primary aortic pathology (either prior open sur-
ical repair of an aneurysm or primary disease) and thus had
ssociated iliofemoral disease. The absence of mortalities in
his study is directly attributed, in part, to the thoroughness of
he preoperative planning for vascular access and appropriate
se of retroperitoneal conduits.
Prosthetic graft infection is a significant concern follow-
ng repair of ABF. In open surgical repair, it is recom-
ended that the prosthetic graft and fresh suture line be
rotected from the repaired bronchial fistula by either wrap-
ing the graft with aneurysmal wall or interposing viable o
282 The Journal of Thoracic and Cardiovascular Surgery ● Maissue such as pleura, intercostal muscle pedicle flap, omen-
um, or pericardial fat pad.7,11 Antibiotic irrigation is rec-
mmended intraoperatively, and the prosthetic graft can
ven be soaked in antibiotic solution prior to implantation.7
LG repair of ABF does not allow for similar maneuvers to
rotect against endoprosthesis infection. In this study, there
ere no endoprosthesis infections. It is unclear as to why
he infection rate for endovascular repair is minimal, but the
LG remains in the center of the aneurysm sac well away
rom the actual fistula and source of contamination. Perhaps
ecause there is minimal tissue trauma associated with the
eployment of the ELG, as opposed to open surgical repair,
he excluded aneurysmal or pseudoaneurysmal cavity is
uch less likely to become contamination or infected. Ad-
itionally, the excluded aneurysmal wall and cavity may
till be vascularized and remain viable, to some degree, after
ndovascular repair from fine collaterals branches that are
ot disrupted with deployment of the ELG. All patients
eceived 3 intravenous doses of perioperative cephalosporin
ntibiotics. Subsequently, no routine postoperative antibi-
tic regimen was followed. In fact, 2 patients received no
ostoperative antibiotics and were discharged home without
ny oral antibiotics. In this limited cohort, there does not
ppear to be an association between postoperative antibiotic
dministration and freedom from graft infection. Additional
tudies are needed before definitive recommendations for
ntibiotic administration can be generated. In the meantime,
e feel it is appropriate to discharge the patients with 1
eek of outpatient oral antibiotics.
This study has several limitations. First, it is a small
eries and has associated limitations for making broader
eneralizations. However, the results are promising for an
ndovascular approach to ABF when taken in the context of
he additional 36 patients reported in the world’s literature.
econd, this is a retrospective review and a subset of pa-
ients taken from a larger series of thoracic endografting
atients from a single center. To better understand the risks
nd benefits of an endovascular approach, a prospective,
andomized study is needed. However, it is unlikely that
uch a study can be conducted due to the rarity of ABF and
he limited number of cases. Most likely, any conclusions
hat will be drawn will be based upon a meta-analysis of the
iterature and from large-scale multicenter national research
rials for endovascular devices in general. Finally, although
he follow-up for patients with ABF treated with an ELG
xtends up to 6.25 years in this study, the mean follow-up is
2.6  28.5 months. Currently, all patients are alive, and
ontinued surveillance of these patients is critical. There is
otential for recurrence of the fistula, as 1 of the patients
eveloped an ABF 6 years following placement of a tho-
acic ELG. It will be important to assess any late graft
nfections, device failures, or migrations or adverse patient
utcomes.
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ETIn conclusion, this study demonstrates that it is possible
o treat patients with ABF using an endovascular approach
nd that the results compare favorably with open surgical
epair. Patients tolerated the procedure well, and hemoptysis
esolved in all 7 patients. There were no deaths, no episodes
f paraplegia, and no endoprosthesis infections. All patients
re still alive and there have been no reinterventions. Care-
ul preoperative planning is essential for optimal results
hen patients are being considered for endovascular repair,
specially with regards to vascular access considerations. In
ur cohort, duration and type of postoperative antibiotics
oes not appear to correlate with freedom from graft infec-
ion. Although endovascular technologies are emerging for
he treatment of many types of aortic pathologies, signifi-
ant questions relating to this therapeutic modality are yet to
e resolved including long-term device durability, improved
ong-term patient outcomes, and economic concerns of in-
reased device cost and expenses related to long-term graft
urveillance with CT. Additional investigation and contin-
ed graft surveillance are critical to help determine the
uture role of endovascular technologies.
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iscussion
r Craig Miller (Stanford, Calif). Thank you, Dr Gelfand and Dr
awkins. Grayson, that was a very nice presentation that we’ve
ome to expect from you.
This is the third report from the Arizona Heart Institute on
ndovascular treatment of aortotracheal fistulas. Before you got
here, there was a report in 2002 with 2 cases. In your large total
xperience reported this year in the Annals you had 4, and now you
ave taken us up to 7. You pointed out in the paper that there are
6 cases in the literature and now with 3 more additional, so 39,
ith an overall mortality rate of 8%, which is pretty darn good
onsidering that a lot of these patients need reoperations and have
ad previous grafts and whatnot. I think that is very encouraging.
he question, therefore, is not can it be done. You and others and
e have shown that it can be done, but how effective and how
and Cardiovascular Surgery ● Volume 133, Number 5 1283
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1
ETurable is it for what can be a devastatingly bad situation? And
ere I think you have provided some very good news with your
ollow-up: 43 29 months going out to 6 years, no late deaths, no
ate infections. It’s almost too good to believe, but it is good news
nd it is very promising and we look forward to more follow-up.
I would like to turn to something that you’ve already broached
nd that’s the legal and the ethical issues at foot here. You’ve
hown us very clearly the amount of work that Dr Diethrich and
he institution had to go through to get a physician-sponsored
ndividual investigator device exemption (IDE) from the Food and
rug Administration. We have also done that, and that allowed
ou to treat these patients, who would otherwise not have qualified
or any of the commercial IDEs. There now are a couple high-risk
DEs that cover this but they are few in number. I want to caution
he audience that if you go home and try this, if you are Gore TAG
ertified, it is going to be off label for an aortobronchial or for an
ortoesophageal fistula or even a dissection. It is going to be off
abel, and you have to be very, very aware that if something
oesn’t go perfectly well, you don’t have a leg to stand on
edicolegally in court. The lawyers are out there just waiting for
his, and there have been all too many examples already—an
bdominal aortic stent graft or a home-brew stent graft or a
ommercial stent graft used for aortic dissection, for example—
here something bad happened, and you just don’t have a leg to
tand on legally unless you have an institutional physician-spon-
ored IDE like you do. That brings me to, what are you doing now?
s your physician-sponsored IDE still current, and do you enroll
hem in that today just to cover yourselves? That’s the first ques-
ion, easy one.
Dr G.H. Wheatley (Phoenix, Ariz). Yes. We applied for, and
uccessfully received, an extension and continuation of that pro-
ocol. Patients who are being treated with aneurysms were origi-
ally included in the protocol, but now that it is Food and Drug
dministration approved for aneurysms; those patients are not
nrolled in the protocol, and so the protocol now only includes
ff-label uses in the high-risk surgical patients.
Dr Miller. So right now, you are shut down until the Food and
rug Administration rules on your extension application?
Dr Wheatley. No, it’s been approved, and we have been
ontinuously enrolling patients without interruption.
Dr Miller. Oh, it’s been renewed and extended. Okay. So
ou’re being judicious and that’s important for those of you who
ight see one of these desperately ill patients roll in some Friday
ight, because even though you are trying to save their lives, the
state of the family may not see it that way later on.
Okay, 7 cases now. Three were aneurysms, 3 were false aneu-
ysms, and 1 traumatic case. Your slide—I’m glad you showed
hat happened to the sac with the serial CT scans thereafter. That
as one of my questions and that information I assume will now
e in the paper. You had 8 patients on that slide, not 7. Can you
xplain where that eighth flyer got in there? Second, could you
laborate on what happened with the patient with 1 traumatic tear,
ho had had a previous stent graft? Was it elsewhere? Was it your
lace? And why that 1 created the complication? And third, I was
little surprised to see that you did not have any giant aortic
enetrating ulcers, atherosclerotic ulcers, which can cause an aor-
otracheal fistula. Any comments there? t
284 The Journal of Thoracic and Cardiovascular Surgery ● MaDr Wheatley. Yes. Thank you, Dr Miller, for your comments
nd certainly thank you for your comments regarding the manu-
cript and we greatly appreciate your insight.
In terms of the eighth one, that was not included in the graph.
t was on the label but it wasn’t there. If you count the actual lines,
here were only 7. It was a benefit of PowerPoint presentations.
Interesting case, I agree. I think that we need to be very
ognizant, and this is 1 of the first that I have been aware of where
patient was 3 years out from a prior ELG repair of a transection.
his patient was badly injured. He had motor vehicle accident,
iver laceration, and brain injury and was hemodynamically unsta-
le, that’s why he was treated with an endoluminal graft, because
f his instability and very significant injury, but did well. Three
ears later he came back with an area distal to that ELG, which
as an ulcerative lesion—no real penetrating ulcer, but there is
ommunication right at the distal end of the graft, perhaps maybe
ecause the graft is eroding. The patient did not have aneurysmal
isease. Maybe there are some long-term consequences of the
LGs that we are not seeing, but certainly I think that this high-
ights that we need to be very scrupulous in following these
atients, and perhaps it may be a long-term complication of ELG
epair in traumatic transections.
Dr Miller. But it wasn’t frankly eroded through to the outside.
Dr Wheatley. No, there was just a communication there that
erhaps may have been related to the graft.
Dr Miller. And it probably wasn’t atherosclerotic disease be-
ause this patient sounds like the typical trauma victim—young,
ealthy, tiny normal aorta and no insurance, right?
Dr Wheatley. Yes, sir.
Dr Miller. You purposely covered the left subclavian once
ithout embolizing it or doing a transposition. You, of course, are
etting yourself up for a type 2 leak and we all know that. Some of
s have done it. No leak occurred in that patient. What is your
urrent practice? Do you leave a patent left subclavian transmitting
ndotension to the sac?
Dr Wheatley. We do. We just reported at (ISMICS) 2 weeks
go, our complete 360-patient experience with covering the left
ubclavian. We cover the left subclavian approximately a third of
he time and only needed a bypass in a few patients out of those
atients that had covered. If we do see a retrograde type 2 leak
rom the subclavian, we will then embolize it using a retrograde
pproach from the brachial, but we manage that usually expect-
ntly. We will usually see that if it is a type 2 endoleak, it is a
inor procedure to come back and embolize the subclavian. If
here is continued sac growth, it is something that we can always
o later, but it is not an emergency need to treat that.
Dr Miller. That’s a good answer and probably the right pos-
ure, but it is a vexing problem because of the strokes occurring
cutely when the left subclavian is covered. I won’t go off on a
angent to ask you how you decide when to revascularize it in
dvance and when not.
Finally, your topic is “Have we gone too far?” and you’re
ushing the envelope. Let me take you 1 step further. How many
ortoesophageal fistulas have you covered with a stent graft, which
e have done, but I think we are kidding ourselves and this is futile
herapy. What is your experience down in Phoenix?
Dr Wheatley. I agree and that’s why I did not include these inhe paper. It would be a natural fit to talk about aortoesophageal
y 2007
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really don’t think that is a good approach, and that’s why I did not
reak these patients out, but really I don’t think that should be even
ried.
Dr Miller. Got reinfected and died like a dog run over in the
treet.
Dr Wheatley. Yes, sir.
Dr Miller. Yeah, I’m afraid we echo that. Thank you foroming to the Western Thoracic.
The Journal of ThoracicDr Wheatley. Thank you.
Dr Robert Cerfolio (Birmingham, Ala.). I had 2 questions but
e only have time for just 1. If you were going to cover a tracheal
stula with an aortic graft, do you now recommend that you put in
graft long enough that you go past or distal to the carina? My
oncern would be that the distal end of that stent is going to erode
nto either the left main stem or the carina unless you go past it. Is
his your recommendation now?Dr Wheatley. Yes.
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